Removal of endogenously released glutamate is mediated primarily by astrocytes and exogenous 13 C-labeled glutamate has been applied to study glutamate metabolism in astrocytes. Likewise, studies have clearly established the relevance of 13 C-labeled acetate as an astrocyte specific metabolic substrate. Recent studies have, however, challenged the arguments used to anchor this astrocyte specificity of acetate and glutamate. The aim of the current study was to evaluate the specificity of acetate and glutamate as astrocyte substrates in brain slices. Acutely isolated hippocampal and cerebral cortical slices from female NMRI mice were incubated in media containing [1,2- 
INTRODUCTION
For many years it has been generally accepted that glutamate and acetate are primarily taken up and metabolized by astrocytes (for reviews see Schousboe [2012] and McKenna et al., [2016] ). Hence, exogenous 13 C-labeled glutamate and acetate combined with the use of NMR and/ or gas chromatography-mass spectrometry (GC-MS) technology have been applied to astrocyte-neuron co-cultures (Sonnewald et al., 1993b) and acute brain slices (Badar-Goffer et al., 1990; Rae et al., 2003; Rowlands et al., 2015) in order to investigate astrocyte metabolism. The astrocytic specificity of these two substrates has, however, recently been questioned (Rae et al., 2012) .
Glutamate is the major excitatory neurotransmitter of the brain. The prevailing view is that when glutamate is released from neurons it is primarily removed and thereby inactivated by adjacent astrocytes (Danbolt, 2001 ; SIGNIFICANCE Brain energy metabolism constitutes the breakdown and build-up of molecules in relation to generating cellular energy and is essential for brain function.
13 C-Labeled molecules have been used to study brain energy metabolism in health and disease (e.g., Alzheimer's disease and aging) for decades. The current research provides new information on the cellular specificity of two such 13 C-labeled molecules when used in brain slices from mice. This information can improve interpretation of data from past and future studies employing these molecular tools and, hence, move forward our understanding of brain energy metabolism in health and disease. Schousboe, 1981 ) that have a high expression level of the main glutamate transporters GLAST (EAAT1, slc1a3) and GLT-1 (EAAT2, slc1a2) (Danbolt, 2001; Gegelashvili and Schousboe, 1997; Storck et al., 1992) . The belief, that glutamate uptake occurs primarily in astrocytes, led to the use of 13 C-or 15 N-labeled glutamate provided exogenously in vitro to study astrocyte metabolism (McKenna et al., 2016; Parpura et al., 2016; Yudkoff et al., 1986) , assuming the uptake and subsequent metabolism of the labeled glutamate would primarily be astrocytic. A considerable body of evidence, however, has arisen, supportive of neuronal GLT-1 expression and potentially a quantitatively significant glutamate uptake into neuronal terminals (reviewed recently by Rimmele and Rosenberg [2016] and Danbolt et al., [2016] ). In particular, expression of GLT-1 in axon terminals capable of mediating glutamate uptake was finally shown in the hippocampus (Chen et al., 2004; Furness et al., 2008) and subsequently also in axon terminals of somatosensory cortex (Melone et al., 2009 ) and striatum (Petr et al., 2013) . Moreover, glutamate transporter GLT-1 mediated currents were ultimately detected in neurons in the hippocampal brain slice (Huang, 2006) . It is still agreed that GLT-1 expression is much higher in astrocytes compared to neurons (Petr et al., 2015) , however, it is unknown whether GLT-1 transporters located on these two cell types contribute equally to glutamate removal from the extracellular space, as discussed by Rimmele and Rosenberg (2016) . Further support of neuronal glutamate uptake is provided by the large capacity of high affinity glutamate uptake in cultured cerebellar granule cells only marginally contaminated with astrocytes (Drejer et al., 1982) and the observation that evoked glutamate release as well as its intracellular concentration in cerebellar granule cells in the presence of extracellular glutamine cannot be maintained in the presence of DL-threo-beta-benzyloxyaspartate (DL-TBOA) which completely blocks the activity of glutamate transporters (Bak et al., 2003; Waagepetersen et al., 2005) .
Acetate or glucose labeled with either 13 C or 14 C have been used to probe brain metabolism since the pioneering work of Waelsch and colleagues in the 1960s using radiolabeled ligands (for historical review of this work see Quastel [1975] and references therein). They found that glucose was metabolized in a compartment containing a large glutamate pool and acetate in a compartment enclosing a small glutamate and a large glutamine pool, later identified as the neuronal and astrocytic compartments, respectively (see, Schousboe [2012] ). Two steps are essential for a cell to metabolize acetate; uptake and transformation into acetyl-Coenzyme A (CoA). Several researchers have studied the presence and catalytic activity of transporters capable of transporting acetate. (Babu et al., 2011; Bergersen et al., 2005; Galic et al., 2003; Martin et al., 2007; Miyauchi et al., 2004; Pierre and Pellerin, 2005; Rae et al., 2012; Rafiki et al., 2003; Simpson et al., 2007; Vannucci and Simpson, 2003) . They have reported that certain subtypes of monocarboxylic acid transporters mediate transport of acetate and are expressed differentially in astrocytes and neurons. In addition, one of the two identified subtypes of sodiumdependent monocarboxylic acid transporters found in neurons has been shown to be capable of transporting acetate. Neurons express transporters with affinity for acetate similar to that of astrocytic transporters (Rae et al., 2012) . Hence, the transport by itself should not be limiting the ability of neurons to utilize acetate. Nevertheless, studies often quoted when arguing for the lack of neuronal acetate uptake include Waniewski and Martin (1998) , showing an 18-times-faster rate of 14 CO 2 production from 14 C-acetate in cortical astrocyte cultures compared to synaptosomes. Moreover, a study by Muir et al., (1986) has shown that [ 3 H]acetate administered to rats and measured post-mortem in brain slices is not detectable within the neuronal cell body whereas it is in astrocytes.
Following acetate uptake, the enzyme acetyl-CoA synthetase (AceCS) converts acetate into acetyl-CoA, which can enter the TCA cycle. As pointed out by Rae et al. (2012) , the acetyl-CoA pool is a branching point for a range of metabolic pathways such as fatty acid synthesis, and formation of N-acetylaspartate and acetylcholine. Recent studies have pointed towards potential differential regulation of AceCS in neurons and astrocytes (Ramadori et al., 2008) , which might in fact be what is underlying the apparent higher metabolism of acetate in astrocytes. Another relevant aspect was provided by Patel et al. (2010) and Deelchand et al. (2009) showing that 90% saturation of acetate consumption was established at plasma acetate concentrations of 6-7 mmol/L, suggesting that acetate utilization in vivo is indeed limited by enzyme activity (AceCS potentially) and not transport. In summary, the literature presents in vivo and in vitro data suggesting that acetate is preferentially metabolized in astrocytes. However, given that both neurons and astrocytes express both AceCS and transporters with sufficient affinity for acetate, it cannot be ruled out that neurons to some extent are capable of taking up and potentially metabolizing acetate.
It is well recognized that the most important precursor for glutamate and GABA synthesis is glutamine (Bradford et al., 1978; Reubi et al., 1978; Ward et al., 1983) . Moreover, de novo synthesis of glutamine (and hence glutamate) from glucose relies on anaplerosis via pyruvate carboxylase (PC) and the activity of glutamine synthetase (GS), enzymes primarily located in astrocytes (Cesar and Hamprecht, 1995; Norenberg and Martinez-Hernandez, 1979; Shank et al., 1985; Sonnewald et al., 1993a; Yu et al., 1983 Parpura et al., 2016; Reubi et al., 1978) . The above considerations may question some of the conclusions drawn from brain slice experiments employing acetate and glutamate as substrates, one of the most important being astrocyte-neuron glutamine transfer (part of neurotransmitter cycling) and its connection to glutamate and GABA synthesis in neurons. Hence, the present study aims at evaluating the specificity of acetate and glutamate as astrocyte substrates in acute brain slices, and investigates the magnitude of astrocyte-neuron glutamine transfer in this preparation. To fulfil this aim, acutely isolated brain slices from cerebral cortex and hippocampus were incubated with 13 C-labeled acetate or glutamate in the absence or presence of methionine sulfoximine (MSO), which is a well-known pharmacological tool to block GS (Lamar and Sellinger, 1965; Sellinger and Weiler, 1963) .
MATERIALS AND METHODS

Materials
Female NMRI mice were purchased from Harlan (Horst, The Netherlands) and housed at Department of Drug Design and Pharmacology, University of Copenhagen. The animals were kept in humidity and temperature-controlled facility, with 12/12h light/dark cycle and free access to water and standard chow. The stable 13 C isotopes [1,2- C]glutamate (99%) were purchased from ISOTEC V R and Cambridge Isotope Laboratories, respectively. L-Methionine-Ssulfoximine (MSO) was purchased from Sigma-Aldrich. All other chemicals used were of the purest grade available from regular commercial sources.
Brain Slice Incubations
Incubation of acutely isolated brain slices was performed as described in Andersen et al. (2017) . Animals were euthanized by cervical dislocation and decapitated. The brain was removed from the cranial vault and quickly submerged in ice-cold artificial cerebrospinal fluid (ACSF), containing in mM: NaCl 128, NaHCO 3 25, D-glucose 10, KCl 3, CaCl 2 2, MgSO 4 1.2, KH 2 PO 4 0.4, pH 5 7.4. The cortices and hippocampi were dissected and sliced (350 mm) using a McIlwain tissue chopper (The Vibratome Company). The slices were kept just below the surface of 10 mL 378C oxygenated (95% CO 2 /5% O 2 ) ACSF 6 5 mM MSO and allowed to recover from slicing for 60 minutes. Subsequently, slices were incubated for 60 minutes in ACSF, containing 5 mM D-glucose and additionally 5 mM [1,2-13 C]acetate, or 0.5 mM [U-
13
C]glutamate, 6 5 mM MSO. 2-10 mM MSO has previously been shown to significantly reduce GS activity in acute brain slices (El Hage et al., 2011) and preliminary experiments revealed no difference between employing 5 and 10 mM MSO in the current slice setup.
Transferring the slices to ice-cold 70% ethanol terminated metabolism. The slices were sonicated on ice, centrifuged at 48C (20,000 g x 20 min) and the supernatant removed. Pellets were saved for protein determination (Pierce method) while the supernatant was lyophilized and reconstituted in water for determination of 13 C-labeling of metabolites and quantification of amino acids, by GC-MS and HPLC analysis, respectively. Four mice were used for this study and all experimental conditions were performed on each individual animal.
Metabolic Mapping by Gas Chromatography-Mass Spectrometry
The method is modified from Mawhinney et al. (1986) and described in detail in Walls et al. (2014) . Aqueous extracts of brain slices were acidified to pH 1-2 with HCl and evaporated to complete dryness under nitrogen flow. Organic extraction was carried out twice, using 96% ethanol and benzene, with evaporation to complete dryness under nitrogen flow between the two extractions. The TCA cycle intermediates and amino acids in the samples were derivatized using N-tert-butyldimethylsilyl-Nmethyl-trifluoroacetamide in the presence of dimethylformamide. The samples were analyzed by gas chromatography (GC, Agilent Technologies 7820A, J&W GC column HP-5MS) coupled to a mass spectrometer (MS, Agilent Technologies 5977E). Isotopic labeling was corrected for the natural abundance of 13 C by standards containing unlabeled metabolites of interest. Standards were treated and analyzed as the samples described above. Data is presented as percentage 13 C-labeling or total nmol of M 1 X, where M is the molecular ion of the given molecule and X is the number of 13 C atoms in the molecule, as described by Biemann (1962) and Walls et al. (2014) .
Amino Acid and Lactate Determination
Quantitative amounts of amino acids in brain slice extracts were determined by reverse phase high performance liquid chromatography (HPLC, Agilent Technologies 1260 Infinity, Agilent ZORBAX Eclipse plus C18 column). Precolumn o-phthalaldehyde derivatization and fluorescent detection (excitation k 5 338 nm, emission k 5 390 nm) were performed. Gradient elution with aqueous mobile phase A (10 mM NaH 2 PO 4 , 10mM Na 2 B 4 O 7 , 0.5 mM NaN 3 , pH 5 8.2) and mobile phase B (acetonitrile 45% : methanol 45% : H 2 O 10%, V:V:V), was used. Mobile phase B increased linearly from 2% to 57% from 0 to 30 minutes, then from 57% to 100% in 0.1 minute, to return again to 2% in minute 33.6 with a total run time of 35 minutes. The amounts of amino acids were determined from standards containing amino acids of interest. Lactate released from the brain slices to the medium during the incubations was determined using the L-lactic acid kit from Boehringer Mannheim/R-Biopharm AG according to the manufacturer's instructions.
Statistical Analysis
Data is presented as means 6 standard error of the mean (SEM). Significant outliers were identified by Grubbs' test (a 5 0.05) and reported in the results section main text or figure legends. Statistically significant differences between the control and the MSO treated group were tested using Student's unpaired t-test. Significance level was set at p < 0.05 and is indicated with a single asterisk in figures. Numerical p-values and corresponding n-values are given in the main text of the results section for significant findings. When an outlier has been removed 'n 5 3-4' is stated. For each 13 C-substrate the statistical significance of the difference in 13 C-labeling between the control and MSO group was tested for eight metabolites (glutamate, glutamine, citrate, malate, aspartate, aketoglutarate, succinate and fumarate). Since the measured variables are depending on each other, no correction for multiple comparisons can easily be applied and we acknowledge the slightly increased risk of false positives. The same holds true for the total metabolite contents measured for three metabolites (glutamate, aspartate and GABA) across the two groups. C]glutamate gives rise to uniformly labeled glutamine (M15) via GS. As seen from Fig. 1 (A  and B) , significant reductions in glutamine 13 C-labeling (%) were observed in extracts from cerebral cortical and hippocampal slices, incubated with [1,2-13 C]acetate (p 5 1.7E-6, n 5 4 and p 5 2.7E-7, n 5 4, respectively) or [U-13 C]glutamate, (p 5 1.6E-4, n 5 4 and p 5 3.1E-6, n 5 4, respectively) in the presence of MSO. This clearly shows that MSO at the applied concentration (5 mM) indeed blocks GS activity effectively in the acute brain slices, leaving only minor residual activity. rise to double labeled TCA cycle intermediates and amino acids. This is the case in both neurons and astrocytes, assuming both cell types metabolize acetate. As seen from Fig. 2 (A) the percentage M12 in cerebral cortical slices was significantly increased for the TCA cycle intermediates citrate (p 5 2.1E-4, n 5 4) and malate (p 5 9.3E-4, n 5 3 -4) as well as the amino acids glutamate (p 5 0.0010, n 5 4) and aspartate (p 5 0.0065, n 5 4) following incubation with [1,2-13 C]acetate in the presence of MSO to block GS. The same was true for hippocampal slices, as seen in Fig. 2 (B) (citrate p 5 1.4E-4, n 5 4; malate p 5 8.1E-4, n 5 3 -4; glutamate p 5 5.5E-6, n 5 4 and aspartate p 5 1.7E-5, n 5 4). Moreover, significant elevations of 13 C-labeling with MSO were observed for a-ketoglutarate M12 in hippocampus (p 5 0.021, n 5 3 -4), and fumarate M12 was higher in both cerebral cortex (p 5 0.0014, n 5 4) and hippocampus (p 5 1.4E-5, n 5 4), whereas the apparent increase in succinate M12 did not reach statistical significance in cerebral cortex (p 5 0.325, n 5 4) nor hippocampus (p 5 0.053, n 5 4) (data not shown). One significant outlier was excluded from hippocampus, MSO treated, aketoglutarate M12 (n 5 3). Subsequent to entry of [U-13 C]glutamate into the mitochondrial compartment the carbon skeleton may be converted into uniformly labeled a-ketoglutarate (M15) via glutamate dehydrogenase or one of the aminotransferases, and further TCA cycle metabolism will give rise to 13 C-labeling in TCA cycle intermediates. Moreover, activity of aspartate aminotransferase will give rise to labeling of aspartate. As shown in Fig. 2 (C and D) , no significant changes in 13 C-labeling were observed in glutamate, malate, aspartate or citrate following incubation with [U-
RESULTS
MSO Inhibits
13 C]glutamate in the presence of MSO for cerebral cortex and hippocampus, respectively. Moreover, no significant changes with MSO were observed for aketoglutarate M15 (p 5 0.99 and 0.11, n 5 4) or fumarate M14 (p 5 0.95 and 0.42, n 5 4) in either cerebral cortex or hippocampus, respectively, whereas succinate M14 exhibited a significant decrease in hippocampus (55%, p 5 0.021, n 5 3-4), but not in cerebral cortex (p 5 0.99, n 5 4) (data not shown). One significant outlier was excluded from hippocampus, MSO treated, succinate M14 (n 5 3). Given that the majority of the total glutamate pool is located in the neuronal compartment (Lanz et al., 2014; Lebon et al., 2002; Patel et al., 2010; Tiwari et al., 2013) , the labeling of this pool must to a large extent reflect the neuronal glutamate pool. Labeling of the neuronal glutamate pool may either originate from astrocyte-provided labeled glutamine or direct neuronal uptake of labeled glutamate. As observed, MSO inhibits GS whereby generation of labeled glutamine from glutamate taken up by astrocytes is abolished. If indeed preferentially astrocytes and not glutamatergic neurons are taking up glutamate, the reduced astrocyte-neuron transfer of labeled glutamine should lead to reduced labeling of the neuronal glutamate pool. This was, however, not the case and the data therefore strongly favors substantial neuronal glutamate uptake. Likewise, if exogenously provided 13 C-labeled glutamate introduces 13 C-labeling in TCA cycle intermediates within the astrocyte and only in the neuronal pools following astrocyte-neuron glutamine transfer, then, GS inhibition should give rise to reduced labeling of the TCA cycle intermediates. MSO had no effect on 13 C-labeling from [U-13 C]glutamate in TCA cycle intermediates, which further supports neuronal glutamate uptake.
Reduced GABA Amounts in Brain Slices Incubated with MSO
Blocking GS with MSO during incubation with [1,2-13 C]acetate of cerebral cortical and hippocampal slices did not significantly affect the contents of aspartate and glutamate, whereas the amount of GABA was significantly decreased in cerebral cortex (40%, p 5 0.0045, n 5 4, Fig. 3 [A]) and hippocampus (31%, p 5 0.047, n 5 4, Fig. 3 [B] ). Moreover, GABA contents measured in slices incubated Results are presented as mean 6 SEM (n 5 4). One significant outlier was excluded from hippocampus, control, malate M12 and cerebral cortex, control, malate M12 for which n 5 3. M1X, molecular weight 1 X. Student's t-test, *: p < 0.05.
with [U-13 C]glutamate showed a trend towards a decrease in the presence of MSO, i.e., 26% for cerebral cortex (p 5 0.051, n 5 4, Fig. 3 [C] ) and 37% for hippocampus (p 5 0.057, n 5 4, Fig. 3 [D] ). Glutamine could not be quantified, as MSO and glutamine have similar retention times. These results suggest that astrocyte-neuron glutamine transfer indeed contributes to GABA synthesis in the current preparations of cerebral cortical and hippocampal slices. Neurotransmitter GABA is synthesized from glutamate only in GABAergic neurons, and labeling of GABA from [1,2-13 C]acetate is therefore a result of neuronal metabolism of acetate or transfer of labeled glutamine from astrocytes to neurons. In the presence of MSO labeling of GABA only occurs via direct neuronal metabolism of acetate. GABA was clearly labeled from [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate and the labeling was reduced significantly (50%) in the presence of MSO in both the cerebral cortex and hippocampus (p 5 0.024, n 5 4 and p 5 0.019, n 5 4, respectively, Fig.  4 ). These results underline that GABAergic neurons indeed must be capable of taking up and metabolizing acetate and that glutamine transfer from astrocytes to GABAergic neurons contributes to approximately 50% of GABA synthesis.
Lactate Release from Brain Slices is Unaffected by MSO
Processing of glucose in glycolysis leads to formation of pyruvate, which can give rise to lactate via lactate dehydrogenase action. Brain cells in culture release lactate to a great extent , and the production and release of lactate provides an indication of glycolytic activity in the preparation. Blocking GS with MSO did not significantly alter the amount of lactate released from the slices into the media during incubation with [1,2-13 C]acetate or [U-13 C]glutamate (Fig. 5 [A and  B] , respectively). Hence, MSO does not appear to affect glycolytic activity in the slices prepared from cerebral cortex or hippocampus. 
DISCUSSION
The aim of this study was to evaluate the specificity of acetate and glutamate as astrocyte substrates in acute brain slices prepared from cerebral cortex and hippocampus. As expected from previous studies using neuron-astrocyte co-cultures, blocking GS in acute brain slices significantly reduced 13 C-labeling in glutamine during incubations with [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] (Dadsetan et al., 2011; Sonnewald et al., 1993b) . This may indicate that in the previous studies GS may not have been completely inhibited by MSO.
MSO led to changes in 13 C-labeling in TCA cycle intermediates and amino acids during incubations with [1,2- 13 C]acetate demonstrating the importance of GS as the link between astrocytic TCA cycle metabolism and generation of glutamine, the primary glutamateprecursor. Glutamate de novo synthesis in astrocytes relies on anaplerosis via PC ( € Oz et al., 2004; Serres et al., 2008) . In the presence of MSO the need for glutamate synthesis is reduced due to the abolished glutamine synthesis. We therefore suggest that the increase in percentage 13 C-labeling in the presence of MSO reflects an accumulation of label in TCA cycle intermediates resulting from a reduced PC activity. In particular, reduced PC activity will lead to lower influx of unlabeled carbon from glucose resulting in increased 13 C-labeling of TCA cycle intermediates.
GABA is known to be mainly synthesized and located in GABAergic neurons (Storm-Mathisen et al., 1983) . GABA was indeed labeled from [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate in the presence of MSO, which blocks GS and consequentially blocks transfer of labeling via glutamine from astrocytes to neurons. This clearly demonstrates that GABAergic neurons of the brain slices take up and metabolize acetate. However, the decrease in total as well as 13 C-labeled amounts of GABA supports the general view that astrocyte-provided glutamine is an important precursor for neuronal GABA synthesis. Our findings suggest that glutamine transfer from astrocytes to GABAergic neurons contributes to approximately 50% of GABA synthesis from acetate. This is in line with a 56% reduction in 13 Clabeling of GABA from [2-
13 C]acetate observed by Sonnewald et al. (1993b) in astrocyte-neuron co-cultures following incubation with MSO. It should be noted, that the abolished astrocyte-to-neuron glutamine delivery in the presence of MSO might have induced acetate metabolism and, hence, larger GABA labeling in GABAergic neurons. Furthermore, it has been shown in multiple studies that glutamine in acutely isolated slices is lost to the medium during incubation. Thus, a recent study in our laboratory, using the same experimental set up, has shown a 80-95% reduction in brain slice glutamine levels following 60 minutes pre-incubation combined with 30-90 minutes incubation with 13 C-labeled glucose or acetate (McNair et al., 2017) . The loss of glutamine may lead to an underestimation of the GABA labeled from astrocyteprovided glutamine during incubation with [1,2-13 C]acetate and, hence, an overestimation of the relative contribution of neuronal GABA synthesis from acetate. Taken together, our data clearly demonstrates that in the current acute slice preparation of cerebral cortex and hippocampus, GABAergic neurons take up and synthesize GABA from acetate, and astrocyte-neuron glutamine transfer occurs, despite the increase of interstitial space observed by others and predicted to potentially compromise this process (Schousboe and Hertz, 1971; Takano et al., 2014) .
We observed that glutamate M12 labeling from [1,2-13 C]acetate increased significantly in the presence of MSO, i.e. from 6-9% to 12-14%. Approximately 10-15% of brain glutamate is believed to be located in astrocytes (Lanz et al., 2014; Lebon et al., 2002; Patel et al., 2010; Tiwari et al., 2013) , and that is therefore the maximal contribution from the astrocyte to glutamate 13 Clabeling. The observed 13 C-labeling of glutamate up to 14% would require an improbable close to 100% labeling of the astrocytic glutamate pool. This indicates that labeling of glutamate in the presence of MSO does not originate from the astrocytic compartment alone and neuronal acetate uptake and metabolism is therefore likely to occur. This is in line with the labeling observed in GABA from [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate metabolism in the presence of MSO, again suggesting neuronal uptake and metabolism of acetate. It should be noted that the increase in overall glutamate labeling does not rule out the possibility of reduced labeling in the neuronal glutamate pool as a consequence of MSO-blocked glutamate-precursor (glutamine) synthesis and astrocyte-neuron transfer.
MSO did not significantly affect 13 C-labeling from [U-13 C]glutamate which strongly suggests that exogenously provided glutamate and potentially also endogenously released neurotransmitter glutamate, may be taken up to a significant extent by neurons. The majority of the glutamate pool is believed to be neuronal (references as above). Hence, it is unlikely that the 50-60% labeling in glutamate M15 (observed with and without MSO) could be obtained solely by label accumulating in astrocytes, and the results are strongly indicative of neuronal glutamate uptake. In case the applied [U-
13 C]glutamate is being taken up primarily by astrocytes, it is hard to explain how 13 C-labeling (%) in other metabolites did not change in the presence of MSO. Given that blockage of GS would lead to accumulation of labeled and unlabeled glutamate in the astrocyte, one would have expected increased 13 C-labeling in TCA cycle intermediates with MSO as observed following incubations with [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate. Based on the results obtained in the present study, glutamate uptake into neurons should be taken into account. This is in line with work by Rosenberg et al. (2015) providing evidence for approximately 50% of glutamate uptake into acute hippocampal brain slices being neuronal. Hence, care should be taken when making conclusions from results obtained from incubations with [ 13 C]glutamate of preparations consisting of both neurons and astrocytes such as acute brain slices. It should be noted that all experiments were performed on female mice and hence sex-specific aspects of the work could not be evaluated.
CONCLUSION
Based on the results obtained from incubations with [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate, it is concluded that acetate is taken up preferentially by astrocytes but also to some extent by GABAergic neurons and most likely glutamatergic neurons as well. The current data proposes that at least 50% of GABA labeling in neurons originates from astrocytic acetate uptake and metabolism, supporting the view that astrocyte-produced glutamine is an important precursor for neuronal GABA synthesis. Furthermore, this provides evidence for astrocyte-neuron glutamine transfer in the present slice incubation setup. Finally, our data clearly demonstrates that neurons take up a considerable fraction of exogenously provided glutamate. Therefore, in preparations containing neurons along with astrocytes this has to be considered.
